Controlled release polymeric ocular delivery of acyclovir

Deshpande, Praful Balavant; Dandagi, Panchaxari Mallappa; Udupa, N.; Gopal, Shavi V.; Jain, Samata S.; Vasanth, Surenalli G.

doi:10.3109/10837450903262017

Cited by 32 publications

(12 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results of the same are depicted in Figure 12. Shelf-life calculated by linear extrapolation by first-order plot was found to be 6 months 16 days and 5 months 21 days for AL-07 and AL-09 (exhibited similar stability) with degradation constant (k) value of 0.0161 and 0.084, respectively (Deshpande et al, 2010). The optimized storage condition for formulations, AL-07 and AL-09, was found to be stable at 5 ± 3 C. The proposed shelf-life (6 months at 5 ± 3 C) is based on available laboratory conditions at small scale.…”

Section: Stability Studiesmentioning

confidence: 98%

PEGylated liposomes of anastrozole for long-term treatment of breast cancer:in vitroandin vivoevaluation

Shavi

Reddy

Raghavendra

et al. 2015

Journal of Liposome Research

Self Cite

View full text Add to dashboard Cite

The aim of present study was to develop conventional and PEGylated (long circulating), liposomes containing anastrozole (ANS) for effective treatment of breast cancer. ANS is a third-generation non-steroidal aromatase inhibitor of the triazole class used for the treatment of advanced and late-stage breast cancer in post-menopausal women. Under such disease conditions the median duration of therapy should be prolonged until tumor regression ends (>31 months). Liposomes were prepared by the thin film hydration method by using ANS and various lipids such as soyaphosphatidyl choline, cholesterol and methoxy polyethylene glycol distearoyl ethanolamine in different concentration ratios and evaluated for physical characteristics, in vitro drug release and stability. Optimized formulations of liposome were studied for in vitro cytotoxic activity against the BT-549 and MCF-7 cell lines and in vivo behavior in Wistar rats. Preformulation studies, both Fourier transform infrared study and differential scanning calorimetry analysis showed no interaction between the drug and the excipients used in the formulations. The optimized formulations AL-07 and AL-09 liposomes showed encapsulation efficiencies in the range 65.12 ± 1.05% to 69.85 ± 3.2% with desired mean particle size distribution of 101.1 ± 5.9 and 120.2 ± 2.8 nm and zeta potentials of -43.7 ± 4.7 and -62.9 ± 3.5 mV. All the optimized formulations followed Higuchi-matrix release kinetics and when plotted in accordance with the Korsemeyer-Peppas method, the n-value 0.5 < n < 1.0 suggests an anomalous (non-Fickian) transport. Likewise, the PEGylated liposomes showed greater tumor growth inhibition on BT-549 and MCF-7 cell lines from in vitro cytotoxicity studies (p < 0.05). Pharmacokinetic study of conventional and PEGylated liposomes in Wistar rats demonstrated a 3.33- and 20.28-fold increase in AUC(0-∞) values when compared to pure drug (p < 0.001). Among the formulations, PEGylated liposomes showed encouraging results by way of their long circulation and sustained delivery properties for effective treatment of breast cancer.

show abstract

Section: Stability Studiesmentioning

confidence: 98%

PEGylated liposomes of anastrozole for long-term treatment of breast cancer:in vitroandin vivoevaluation

Shavi

Reddy

Raghavendra

et al. 2015

Journal of Liposome Research

Self Cite

View full text Add to dashboard Cite

show abstract

“…Novel technologies like Ocusert ® , Ocufit ® SR, Minidisc, etc., are capable of reducing the systemic absorption of ocularly absorbed drug. [22] Ocular inserts are biodegradable polymeric systems are being developed in order to attain better ocular bioavailability and sustained action of ocular drugs. Ocular inserts are the solid devices intended to be placed in the conjunctival sac and to deliver the drug at relatively slow rate.…”

Section: Formulation Approaches Of Antiviral and Antiretroviral Agentsmentioning

confidence: 99%

Novel drug delivery approaches on antiviral and antiretroviral agents

Sharma

Chawla

Arora

et al. 2012

J Adv Pharm Technol Res

View full text Add to dashboard Cite

Viruses have the property to replicate very fast in host cell. It can attack any part of host cell. Therefore, the clinical efficacy of antiviral drugs and its bioavailability is more important concern taken into account to treat viral infections. The oral and parenteral routes of drug administration have several shortcomings, however, which could lead to the search for formulating better delivery systems. Now, a day's novel drug delivery systems (NDDS) proved to be a better approach to enhance the effectiveness of the antivirals and improve the patient compliance and decrease the adverse effect. The NDDS have reduced the dosing frequency and shorten the duration of treatment, thus, which could lead the treatment more cost-effective. The development of NDDS for antiviral and antiretroviral therapy aims to deliver the drug devoid of toxicity, with high compatibility and biodegradability, targeting the drug to specific sites for viral infection and in some instances it also avoid the first pass metabolism effect. This article aims to discuss the usefulness of novel delivery approaches of antiviral agents such as niosomes, microspheres, microemulsions, nanoparticles that are used in the treatment of various Herpes viruses and in human immunodeficiency virus (HIV) infections.

show abstract

“…However, any drug/CD inclusion complex could be included in a more sophisticated system for the controlled release of drugs. Deshpande et al incorporated the inclusion complex of the poorly water soluble acyclovir (ACV) with β-CD into a polymeric matrix of hydroxypropyl methylcellulose sandwiched between two rate-controlling membranes of cellulose acetate phthalate [62]. In this design, the aqueous solubility and the dissolution rate of the drug were increased by complexation, while a controlled release of up to 20 h was achieved using the biodegradable polymeric membranes.…”

Section: Figure 3 Stability Of Natamycin and Natamycin/γ-cd Inclusiomentioning

confidence: 97%

“…Rifampicin Oral E. coli, S. aureus ND [44] HPβ-CD Solubility and stability Ciprofloxacin Ocular ND ND [33] γ-CD Stability Dicloxacillin ND ND ND [34] β-CD Stability Erythromycin Parenteral S. aureus ND [30] β-, γ-CD Stability Amoxicillin Oral ND ND [35] β-CD Stability Doxycycline ND E. coli ND [38] HPβ-CD Stability Doxycycline Ocular ND ND [24] HPβ-CD Stability Doxycycline Ocular E. coli, P. aeruginosa, S. aureus ND [39] HPβ-CD Stability Ciprofloxacin Ocular P. aeruginosa, S. aureus ND [32] β-CD Controlled release TSC Ocular P. aeruginosa, S. aureus ND [48] Viral β-CD Solubility Acyclovir Ocular ND ND [62] HPβ-CD Solubility Saquinavir Oral ND ND [56] HPβ-CD Solubility Saquinavir Vaginal HIV-infected MT-4 cells ND [61] β-, HPβ-, Mβ-CD Solubility UC781 Vaginal ND ND [60] β-CD Solubility Acyclovir ND Two clinical isolates of HSV-1 ND [63] HPβ-, HPγ-, Mβ-CD Solubility and stability TSC ND ND ND [6] HPβ-CD Solubility and stability TSC ND Hepatitis C virus ND [107] HPβ-CD Solubility and stability Ganciclovir Ocular ND Rabbit (ex vivo assay) [51] HBenβ-CD Solubility and bioavailability Saquinavir Oral ND Rat [55] Mβ-CD Solubility and bioavailability Saquinavir Oral ND Rat …”

Section: Application Of Cyclodextrins In Infectious Diseasesmentioning

confidence: 99%

Cyclodextrin Complexes for Treatment Improvement in Infectious Diseases

Imperiale

Sosnik

2015

Nanomedicine (Lond.)

View full text Add to dashboard Cite

Infectious diseases are a heterogeneous group of maladies that represent a serious burden to healthcare systems worldwide. Most of the available antimicrobial drugs display poor biopharmaceutical properties that compromise their effectiveness. Cyclodextrins (CDs) are cyclic oligosaccharides of glucopyranose formed by a variable number of repeating units that combine a hydrophilic surface with a hydrophobic cavity. The production of drug/CD complexes has become one of the most extensively investigated technology approaches to improve the stability, solubility, dissolution rate and bioavailability of drugs. The present work overviews the applications of CDs for the formulation of anti-infective agents along with the most relevant administration routes. Finally, an update on the complexes with CDs available on the market to treat infectious diseases is presented.

show abstract

Controlled release polymeric ocular delivery of acyclovir

Cited by 32 publications

References 15 publications

PEGylated liposomes of anastrozole for long-term treatment of breast cancer:in vitroandin vivoevaluation

PEGylated liposomes of anastrozole for long-term treatment of breast cancer:in vitroandin vivoevaluation

Novel drug delivery approaches on antiviral and antiretroviral agents

Cyclodextrin Complexes for Treatment Improvement in Infectious Diseases

Contact Info

Product

Resources

About